Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
NCI invites studies on how bariatric surgery affects cancer risk to attract researchers focusing on long-term cancer effects, not just weight loss or diabetes outcomes.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Resubmission/revision) | January 7, 2028 (Closing)
Funding Amounts: Up to $500,000 in direct costs per year for up to 5 years; no cost sharing required
Summary: Supports investigator-initiated research on biological mechanisms linking bariatric surgery to cancer risk in animal models, humans, or both.
Key Information: Studies must link mechanistic analyses of tissue or bodily fluid samples to cancer endpoints, not biomarkers alone.
Description
The National Cancer Institute (NCI) supports investigator-initiated R01 studies investigating how bariatric surgery affects cancer risk. The program seeks to bring bariatric surgery researchers into cancer research, moving beyond shorter-term outcomes such as weight loss and diabetes. Responsive projects may use animal models, human studies, or both, with planned studies focusing on sleeve gastrectomy and Roux-en-Y gastric bypass, the two commonly used procedures.
Research may examine surgery-specific versus weight-loss effects, differences by sex or racial or ethnic background, colorectal cancer risk, genetic predisposition, or microbiome-mediated mechanisms. The central goal is to connect biological mechanisms with actual cancer outcomes and identify pathways relevant to cancer prevention. Clinical trials are optional.
